Mixed news for PI-88 in cancer trials
Australian drugmaker Progen Pharmaceuticals says that its developmental anticancer agent PI-88 failed to meet it primary efficacy goal in a trial examining it as a treatment for non-small cell lung cancer. The firm explained that the drug, in combination with docetaxel, failed to significantly improve progression-free survival after six months, compared with docetaxel alone.
Progen said that the data was such that no further examination of the PI-88/docetaxel combination in NSCLC is warranted, given that it also failed to improve various secondary endpoints, such as time to disease progression, overall survival rate and certain quality of life measures.
FDA fast tracks PI-88 for liver cancer
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze